albumin paclitaxel + carboplatin + pyrotinib + trastuzumab

This is a four-drug combination regimen consisting of: - **Albumin-bound paclitaxel (nab-paclitaxel):** a microtubule inhibitor formulated with human albumin to improve solubility and delivery. - **Carboplatin:** a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis. - **Pyrotinib:** an irreversible small molecule tyrosine kinase inhibitor targeting HER1 (EGFR), HER2, and HER4 receptors. - **Trastuzumab:** a monoclonal antibody targeting the extracellular domain of the HER2 receptor. This combination is used as neoadjuvant therapy for patients with early or locally advanced HER2-positive breast cancer. The regimen leverages dual anti-HER2 blockade (pyrotinib plus trastuzumab) alongside cytotoxic chemotherapy (albumin-bound paclitaxel and carboplatin) to maximize tumor response. Pyrotinib provides pan-HER inhibition, while trastuzumab mediates antibody-dependent cellular cytotoxicity and blocks ligand-independent signaling. Albumin-bound paclitaxel disrupts microtubule function, and carboplatin causes DNA damage leading to cell death. Clinical studies have shown this combination achieves high rates of pathological complete response in the neoadjuvant setting for HER2-positive breast cancer, with manageable safety profiles[2][3][5]. The main indication is for treatment-naive women with early or locally advanced (stage II–III) HER2-positive breast cancer[2].

Other names

nab-paclitaxel + carboplatin + pyrotinib + trastuzumabalbumin-bound paclitaxel + carboplatin + pyrotinib + trastuzumab